Latest Elan Corporation Plc (ELN) Headlines
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Shares of ELN Up 59.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 10, 11:02AM CDT
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 13 months, Elan has returned 59.37% as of today's recent price of $18.12.
Prothena Announces Appointment of Chief Business Officer
Thomson Reuters ONE - Mon Mar 03, 3:05PM CST
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena's demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena's previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease and other related synucleinopathies.
Elan Has Returned 59.4% Since SmarTrend Recommendation (ELN)
Comtex SmarTrend(R) - Mon Mar 03, 9:40AM CST
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 12 months, Elan has returned 59.37% as of today's recent price of $18.12.
TerraX Closes Private Placement for $675,000
Marketwire - Wed Feb 12, 2:10PM CST
TerraX Minerals Inc. (TSX VENTURE: TXR)(FRANKFURT: TX0) has closed its previously announced non-brokered private placement of 1,500,000 units at $0.45 per unit, with two placees, for gross proceeds of $675,000. Each unit consists of one common share and one-half of one share purchase warrant, with each full warrant entitling the holder to purchase an additional common share at an exercise price of $0.51 per share until February 12, 2016. The shares and any shares acquired on the exercise of warrants will be subject to a hold period expiring on June 13, 2014. Finders' fees of $31,500 were paid with respect to this placement along with the issuance of 70,000 finders' warrants exercisable at $0.51 until February 12, 2016.
Kohl's Teams Up with Katie Holmes to Encourage Women to Start the Conversation About Breast Cancer
Business Wire - Wed Feb 12, 7:00AM CST
Kohl's Department Stores (NYSE: KSS) and Katie Holmes invite women everywhere to start a conversation about their breast health in an effort to confront the "pink elephant in the room" - breast cancer - and support the fight. As part of this initiative, Kohl's will donate up to $1 million to Susan G. Komen(R) to help support the cause.
OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecasts to 2017
PR Newswire - Tue Feb 11, 5:25AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Elan Shares Up 59.4% Since SmarTrend's Buy Recommendation (ELN)
Comtex SmarTrend(R) - Fri Feb 07, 11:07AM CST
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 12 months, Elan has returned 59.37% as of today's recent price of $18.12.
Adult Entertainment Consumption Changes Modern Relationship Dynamics, States Cam4.com
PR Newswire - Wed Feb 05, 8:45AM CST
Social networking webcam site Cam4.com announces recent survey findings point to adult entertainment consumerism as healthy, positive, and "normal," rather than shameful. The survey, conducted by France's leading survey institute, IFOP, also shows couples find Internet-based sex games and activities to be a relationship enhancement tool.
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
Biogen Idec's Profit Soars 56% as Tecfidera Sales Take Off
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 29, 11:40AM CST
Biopharmaceutical behemoth Biogen Idec showed investors this morning why having a niche focus on one particular disease -- in this case multiple sclerosis -- isn't a bad way to turn a sizable profit. In its fourth-quarter earnings release ,...
Elan Up 59.4% Since SmarTrend Uptrend Call (ELN)
Comtex SmarTrend(R) - Thu Jan 16, 4:55PM CST
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 11 months, Elan has returned 59.37% as of today's recent price of $18.12.
Scripps Networks Interactive names Tamara Franklin as EVP of Digital
M2 - Thu Jan 16, 10:44AM CST
Scripps Networks Interactive Inc (NYSE:SNI) announced on Wednesday the appointment of Tamara Franklin as executive vice president of digital of the company.
Nanotechnology Drug Delivery Market in the US 2012-2016 with Celgene Corp., Novartis AG and SkyePharma plc. Dominating
M2 - Wed Mar 12, 11:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3r7bw6/nanotechnology) has announced the addition of the "Nanotechnology Drug Delivery Market in the US 2012-2016" report to their offering. The analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market. Key vendors dominating this space include Alkermes plc., Celgene Corp., Novartis AG and SkyePharma plc. Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd. Commenting on the report, an analyst from the Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.' For more information visit http://www.researchandmarkets.com/research/3r...technology About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Shares of ELN Up 59.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Mar 10, 11:02AM CDT
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 13 months, Elan has returned 59.37% as of today's recent price of $18.12.
Prothena Announces Appointment of Chief Business Officer
Thomson Reuters ONE - Mon Mar 03, 3:05PM CST
DUBLIN, Ireland, March 3, 2014 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a clinical stage biotechnology company focused on the discovery, development and commercialization of novel antibodies for the potential treatment of diseases that involve protein misfolding or cell adhesion, announced today the promotion of Tara Nickerson, PhD, MBA, to Chief Business Officer. Dr. Nickerson is responsible for leading corporate and business development, as well as alliance management efforts at Prothena. Prior to this appointment, Dr. Nickerson held the position of Head of Corporate and Business Development at Prothena, where she was instrumental during Prothena's demerger from Elan Corporation Limited (formerly Elan Corporation, plc) and led the team that developed Prothena's previously announced worldwide collaboration with Roche to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease and other related synucleinopathies. Elan Has Returned 59.4% Since SmarTrend Recommendation (ELN)
Comtex SmarTrend(R) - Mon Mar 03, 9:40AM CST
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 12 months, Elan has returned 59.37% as of today's recent price of $18.12.
TerraX Closes Private Placement for $675,000
Marketwire - Wed Feb 12, 2:10PM CST
TerraX Minerals Inc. (TSX VENTURE: TXR)(FRANKFURT: TX0) has closed its previously announced non-brokered private placement of 1,500,000 units at $0.45 per unit, with two placees, for gross proceeds of $675,000. Each unit consists of one common share and one-half of one share purchase warrant, with each full warrant entitling the holder to purchase an additional common share at an exercise price of $0.51 per share until February 12, 2016. The shares and any shares acquired on the exercise of warrants will be subject to a hold period expiring on June 13, 2014. Finders' fees of $31,500 were paid with respect to this placement along with the issuance of 70,000 finders' warrants exercisable at $0.51 until February 12, 2016.
Kohl's Teams Up with Katie Holmes to Encourage Women to Start the Conversation About Breast Cancer
Business Wire - Wed Feb 12, 7:00AM CST
Kohl's Department Stores (NYSE: KSS) and Katie Holmes invite women everywhere to start a conversation about their breast health in an effort to confront the "pink elephant in the room" - breast cancer - and support the fight. As part of this initiative, Kohl's will donate up to $1 million to Susan G. Komen(R) to help support the cause.
OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecasts to 2017
PR Newswire - Tue Feb 11, 5:25AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
Elan Shares Up 59.4% Since SmarTrend's Buy Recommendation (ELN)
Comtex SmarTrend(R) - Fri Feb 07, 11:07AM CST
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 12 months, Elan has returned 59.37% as of today's recent price of $18.12.
Adult Entertainment Consumption Changes Modern Relationship Dynamics, States Cam4.com
PR Newswire - Wed Feb 05, 8:45AM CST
Social networking webcam site Cam4.com announces recent survey findings point to adult entertainment consumerism as healthy, positive, and "normal," rather than shameful. The survey, conducted by France's leading survey institute, IFOP, also shows couples find Internet-based sex games and activities to be a relationship enhancement tool.
Ignyta Appoints Matthew Onaitis as General Counsel
Business Wire - Mon Feb 03, 6:00AM CST
Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that Matthew Onaitis has been appointed to the newly created role of General Counsel and Secretary. Mr. Onaitis was previously Senior Vice President, General Counsel and Secretary of Trius Therapeutics, Inc., where he led the legal and compliance functions through Trius' acquisition by Cubist Pharmaceuticals, Inc. in September 2013. Mr. Onaitis assisted Cubist with integration activities through December 2013. Prior to Trius, Mr. Onaitis was Senior Vice President, General Counsel and Secretary of Somaxon Pharmaceuticals, Inc. from 2006 until Somaxon's acquisition by Pernix Therapeutics Holdings, Inc. in March 2013. Mr. Onaitis also previously served as Associate General Counsel for the oncology strategic business unit of Biogen Idec Inc. and as Director of Legal Affairs of Elan Corporation, plc.
Biogen Idec's Profit Soars 56% as Tecfidera Sales Take Off
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 29, 11:40AM CST
Biopharmaceutical behemoth Biogen Idec showed investors this morning why having a niche focus on one particular disease -- in this case multiple sclerosis -- isn't a bad way to turn a sizable profit. In its fourth-quarter earnings release ,...
Elan Up 59.4% Since SmarTrend Uptrend Call (ELN)
Comtex SmarTrend(R) - Thu Jan 16, 4:55PM CST
SmarTrend identified an Uptrend for Elan (NYSE:ELN) on February 25th, 2013 at $11.37. In approximately 11 months, Elan has returned 59.37% as of today's recent price of $18.12.
Scripps Networks Interactive names Tamara Franklin as EVP of Digital
M2 - Thu Jan 16, 10:44AM CST
Scripps Networks Interactive Inc (NYSE:SNI) announced on Wednesday the appointment of Tamara Franklin as executive vice president of digital of the company.
